{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:34:46Z","timestamp":1785764086306,"version":"3.56.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["2021T055"],"award-info":[{"award-number":["2021T055"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Amsterdam UMC Fellowship"},{"name":"Dutch Gastroenterology Foundation"},{"name":"ZONMW-VICI","award":["09150182010020"],"award-info":[{"award-number":["09150182010020"]}]},{"name":"Dutch Diabetes Foundation"},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TKI-PPP health-Holland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims\/hypothesis<\/jats:title>\n                  <jats:p>The prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 1 diabetes remain unclear. Therefore, we investigated the prevalence and severity of MASLD in type 1 diabetes and assessed which clinical features are most important in predicting MASLD severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 453 individuals with type 1 diabetes (41.6 \u00b1 15.0 years, 64% female, body mass index [BMI] 25.4 \u00b1 4.2\u2005kg\/m2, and HbA1c 55.6 \u00b1 12\u2005mmol\/mol) underwent vibration-controlled transient elastography (VCTE), with a controlled attenuation parameter (CAP) score for steatosis (\u2265280.0\u2005dB\/m) and a liver stiffness measurement (LMS) for fibrosis (\u22658.0\u2005kPa). A machine learning Extra-Trees classification model was performed to assess the predictive power of the clinical features associated with type 1 diabetes with respect to steatosis and fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The prevalence of hepatic steatosis and fibrosis was 9.5% (95% CI, 6.8-12.2) and 3.5% (95% CI, 1.8-5.2). Higher LMS was associated with a longer duration of type 1 diabetes (median 30.5 [IQR 18.0-39.3] years vs 15.0 [IQR 6.0-27.0] years), and individuals were older, had a higher BMI (mean 27.8 \u00b1 5.2 vs 25.3 \u00b1 4.1\u2005kg\/m2), and a higher CAP score (mean 211.4 \u00b1 51.7\u2005dB\/m vs 241.4 \u00b1 75.6\u2005dB\/m). The most important predictive features of fibrosis were duration of type 1 diabetes, age, and systolic blood pressure, with a mean \u00b1 SD area under the curve of 0.73 \u00b1 0.03.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Individuals with type 1 diabetes and high blood pressure, older age, higher BMI, and longer duration of disease could be considered at high-risk for developing MASLD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae043","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:30:40Z","timestamp":1714372240000},"page":"391-400","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4166-5045","authenticated-orcid":false,"given":"Coco M","family":"Fuhri Snethlage","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham S","family":"Meijnikman","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Linde","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rampanelli","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Voermans","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"},{"name":"HORAIZON Technology B.V. Delft , GZ Delft 2625 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz A K","family":"Callender","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pleun","family":"de Groen","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart O","family":"Roep","sequence":"additional","affiliation":[{"name":"Internal Medicine, Leids Universitair Medisch Centrum , Leiden, ZA 2333 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl H","family":"van Raalte","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-5034","authenticated-orcid":false,"given":"Filip K","family":"Knop","sequence":"additional","affiliation":[{"name":"Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen , 2900 Hellerup , Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , 2200 Copenhagen , Denmark"},{"name":"Steno Diabetes Center Copenhagen , Department of Clinical and Translational Research, 2730 Herlev , Denmark"},{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen , 2200 Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan G","family":"Holleboom","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-7659","authenticated-orcid":false,"given":"Max","family":"Nieuwdorp","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nordin M J","family":"Hanssen","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam , Amsterdam, AZ 1105 , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"10","key":"2024061711263416800_lvae043-B1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2024061711263416800_lvae043-B2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"Ilonen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2024061711263416800_lvae043-B3","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.2337\/dc12-2109","article-title":"The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the diabetes control and complications\/epidemiology of diabetes interventions and complications cohort","volume":"36","author":"Jacobson","year":"2013","journal-title":"Diabetes Care"},{"issue":"25","key":"2024061711263416800_lvae043-B4","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"2024061711263416800_lvae043-B5","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.jhepr.2023.100753","article-title":"Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes","volume":"5","author":"Mertens","year":"2023","journal-title":"JHEP Reports"},{"issue":"9","key":"2024061711263416800_lvae043-B6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2024061711263416800_lvae043-B7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"2024061711263416800_lvae043-B8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"2024061711263416800_lvae043-B9","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"issue":"6","key":"2024061711263416800_lvae043-B10","doi-asserted-by":"crossref","first-page":"e168-e185","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024061711263416800_lvae043-B11","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211055557","article-title":"NAFLD in type 1 diabetes: overrated or underappreciated?","volume":"12","author":"Mertens","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"2024061711263416800_lvae043-B12","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"2024061711263416800_lvae043-B13","doi-asserted-by":"crossref","first-page":"109827","DOI":"10.1016\/j.diabres.2022.109827","article-title":"Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes","volume":"186","author":"de Vries","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2024061711263416800_lvae043-B14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and management of obesity in U.S. adults with type 1 diabetes","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"issue":"5","key":"2024061711263416800_lvae043-B15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/joim.12462","article-title":"Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia","volume":"279","author":"Junker","year":"2016","journal-title":"J Intern Med"},{"issue":"6","key":"2024061711263416800_lvae043-B16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.numecd.2014.01.013","article-title":"Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes","volume":"24","author":"Calanna","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"2024061711263416800_lvae043-B17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/NT.0000000000000512","article-title":"Dietary guidelines for Americans, 2020-2025: understanding the scientific process, guidelines, and key recommendations","volume":"56","author":"Snetselaar","year":"2021","journal-title":"Nutr Today"},{"issue":"11","key":"2024061711263416800_lvae043-B18","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"2024061711263416800_lvae043-B19","article-title":"Residual \u03b2-cell function is associated with longer time in range in individuals with type 1 diabetes","volume":"online ahead of print","author":"Fuhri Snethlage","year":"2023","journal-title":"Diabetes Care"},{"key":"2024061711263416800_lvae043-B20","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"2024061711263416800_lvae043-B21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archinte.1971.00310240115015","article-title":"Angina pectoris and the rose questionnaire","volume":"128","author":"Heyden","year":"1971","journal-title":"Arch Intern Med"},{"key":"2024061711263416800_lvae043-B22","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2147\/OPTH.S267993","article-title":"Self-reported awareness of retinopathy severity in diabetic patients","volume":"14","author":"Qaseem","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"2024061711263416800_lvae043-B23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1464-5491.2012.03644.x","article-title":"Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications","volume":"29","author":"Herman","year":"2012","journal-title":"Diabet Med"},{"issue":"3","key":"2024061711263416800_lvae043-B24","first-page":"181","article-title":"Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes","volume":"14","author":"Besser","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"2024061711263416800_lvae043-B25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2337\/dc10-2114","article-title":"Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes","volume":"34","author":"Besser","year":"2011","journal-title":"Diabetes Care"},{"issue":"9","key":"2024061711263416800_lvae043-B26","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1464-5491.2011.03272.x","article-title":"Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes","volume":"28","author":"Jones","year":"2011","journal-title":"Diabet Med"},{"issue":"1","key":"2024061711263416800_lvae043-B27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/diab.26.1.30","article-title":"Quantitation of human pancreatic beta-cell function by immunoassay of C-peptide in urine","volume":"26","author":"Horwitz","year":"1977","journal-title":"Diabetes"},{"issue":"1","key":"2024061711263416800_lvae043-B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"2024061711263416800_lvae043-B29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/2050640619900820","article-title":"Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis","volume":"8","author":"Semmler","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"2024061711263416800_lvae043-B30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jhep.2010.06.022","article-title":"Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis","volume":"54","author":"Gaia","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"2024061711263416800_lvae043-B31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"2024061711263416800_lvae043-B32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores","volume":"78","author":"Sanyal","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"2024061711263416800_lvae043-B33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10994-006-6226-1","article-title":"Extremely randomized trees","volume":"63","author":"Geurts","year":"2006","journal-title":"Mach Learn"},{"key":"2024061711263416800_lvae043-B34","doi-asserted-by":"crossref","DOI":"10.1137\/1.9781611970319","volume-title":"The Jackknife, the Bootstrap and Other Resampling Plans","author":"Efron","year":"1982"},{"issue":"12","key":"2024061711263416800_lvae043-B35","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","article-title":"Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"105","author":"de Vries","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024061711263416800_lvae043-B36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2337\/dc18-0465","article-title":"C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase","volume":"41","author":"Shields","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"2024061711263416800_lvae043-B37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41440-022-01117-6","article-title":"Mechanisms underlying the bidirectional association between nonalcoholic fatty liver disease and hypertension","volume":"46","author":"Nakagami","year":"2023","journal-title":"Hypertens Res."},{"issue":"1","key":"2024061711263416800_lvae043-B38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-013-9388-5","article-title":"Structural changes in the myocardium during diabetes-induced cardiomyopathy","volume":"19","author":"Adeghate","year":"2014","journal-title":"Heart Fail Rev"},{"issue":"1","key":"2024061711263416800_lvae043-B39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s13300-019-00729-5","article-title":"Insulin resistance in type 1 diabetes mellitus and its association with patient\u2019s micro- and macrovascular complications, sex hormones, and other clinical data","volume":"11","author":"\u0160imonien\u0117","year":"2020","journal-title":"Diabetes Ther"},{"key":"2024061711263416800_lvae043-B40","doi-asserted-by":"crossref","first-page":"768576","DOI":"10.3389\/fphar.2021.768576","article-title":"Hepatopathy associated with type 1 diabetes: distinguishing non-alcoholic fatty liver disease from glycogenic hepatopathy","volume":"12","author":"Mertens","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"2024061711263416800_lvae043-B41","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/19322968211069177","article-title":"Optimal data collection period for continuous glucose monitoring to assess long-term glycemic control: revisited","volume":"17","author":"Cichosz","year":"2022","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"2024061711263416800_lvae043-B42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12902-021-00782-x","article-title":"DPARD: rationale, design and initial results from the Dutch national diabetes registry","volume":"21","author":"Bak","year":"2021","journal-title":"BMC Endocr Disord"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae043\/57350338\/lvae043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/5\/391\/58250533\/lvae043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/5\/391\/58250533\/lvae043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:27:23Z","timestamp":1718623643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/5\/391\/7659495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae043","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,4,29]]}}}